Enliven Therapeutics, Inc. (ELVN)Healthcare | Biotechnology | Boulder, United States | NasdaqGS
57.86 USD
-2.64
(-4.364%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 57.69 -0.17 (-0.166%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:07 a.m. EDT
The investment case for Enliven Therapeutics is fundamentally broken by a catastrophic multi-year price collapse and deteriorating financial health. Despite a 'strong buy' analyst recommendation and a recent public offering, the stock has lost over 80% of its value over the last five years, with the most recent annual return being negative. The company is burning significant cash, reporting negative free cash flow, and carrying negative earnings per share, while the balance sheet shows a massive disconnect between the current price and book value. The options market confirms this bearish sentiment, with traders aggressively buying cheap put insurance at strikes far below the current price, effectively betting against any recovery. While the recent capital raise might temporarily prop up the share price, the underlying business fundamentals—characterized by sustained losses and a steep equity curve—make this a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.121877 |
| AutoTheta | 0.140350 |
| AutoETS | 0.140515 |
| AutoARIMA | 0.227834 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 17.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.106 |
| Excess Kurtosis | -1.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.169 |
| Market Cap | 4,239,446,272 |
| Forward P/E | -24.74 |
| Beta | 0.24 |
| Website | https://www.enliventherapeutics.com |
As of Aug. 22, 2026, 1:07 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 15, 17.5, 20, 25) compared to negligible call volume. The implied volatility skew is extreme, with deep OTM puts trading at significantly higher IV than calls, indicating a market consensus that the primary risk is a sharp decline rather than a rally. Call activity is sparse and concentrated near the money, suggesting limited speculative appetite for upside moves.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9847064 |
| Address1 | 6,200 Lookout Road |
| All Time High | 250.84 |
| All Time Low | 3.896 |
| Ask | 58.4 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 756,510 |
| Average Daily Volume3 Month | 1,437,212 |
| Average Volume | 1,437,212 |
| Average Volume10Days | 756,510 |
| Beta | 0.241 |
| Bid | 43.54 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 12.22 |
| City | Boulder |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 57.86 |
| Current Ratio | 64.073 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 61.18 |
| Day Low | 57.77 |
| Debt To Equity | 0.169 |
| Display Name | Enliven Therapeutics |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -124,284,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -26.921 |
| Enterprise Value | 3,345,801,216 |
| Eps Current Year | -1.846 |
| Eps Forward | -2.33833 |
| Eps Trailing Twelve Months | -1.65 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 54.2633 |
| Fifty Day Average Change | 3.5966988 |
| Fifty Day Average Change Percent | 0.06628234 |
| Fifty Two Week Change Percent | 198.47064 |
| Fifty Two Week High | 62.32 |
| Fifty Two Week High Change | -4.459999 |
| Fifty Two Week High Change Percent | -0.0715661 |
| Fifty Two Week Low | 14.785 |
| Fifty Two Week Low Change | 43.075 |
| Fifty Two Week Low Change Percent | 2.913426 |
| Fifty Two Week Range | 14.785 - 62.32 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,584,019,800,000 |
| Float Shares | 60,522,381 |
| Forward Eps | -2.33833 |
| Forward P E | -24.744156 |
| Free Cashflow | -45,255,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 67 |
| Fullday Change | -2.64 |
| Fullday Change Percent | -4.36364 |
| Fullday Price | 57.6944 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.062230002 |
| Held Percent Institutions | 1.13763 |
| Implied Shares Outstanding | 73,270,761 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado. |
| Long Name | Enliven Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 4,239,446,272 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_693128628 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -105,927,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,432,881,040 |
| Number Of Analyst Opinions | 10 |
| Open | 60.4 |
| Operating Cashflow | -66,939,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 720 647 8519 |
| Post Market Change | -0.16559982 |
| Post Market Change Percent | -0.28620777 |
| Post Market Price | 57.6944 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 60.5 |
| Price Eps Current Year | -31.343447 |
| Price Hint | 2 |
| Price To Book | 4.734861 |
| Profit Margins | 0.0 |
| Quick Ratio | 63.213 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.08333 |
| Region | US |
| Regular Market Change | -2.64 |
| Regular Market Change Percent | -4.36364 |
| Regular Market Day High | 61.18 |
| Regular Market Day Low | 57.76 |
| Regular Market Day Range | 57.76 - 61.18 |
| Regular Market Open | 60.4 |
| Regular Market Previous Close | 60.5 |
| Regular Market Price | 57.86 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 584,960 |
| Return On Assets | -0.109969996 |
| Return On Equity | -0.15312 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 73,270,761 |
| Shares Percent Shares Out | 0.11270001 |
| Shares Short | 8,258,991 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 8,651,596 |
| Short Name | Enliven Therapeutics, Inc. |
| Short Percent Of Float | 0.16239999 |
| Short Ratio | 8.53 |
| Source Interval | 15 |
| State | CO |
| Symbol | ELVN |
| Target High Price | 82.0 |
| Target Low Price | 64.0 |
| Target Mean Price | 73.9 |
| Target Median Price | 74.0 |
| Total Cash | 895,155,008 |
| Total Cash Per Share | 12.217 |
| Total Debt | 1,510,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.65 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 36.4894 |
| Two Hundred Day Average Change | 21.370602 |
| Two Hundred Day Average Change Percent | 0.58566606 |
| Type Disp | Equity |
| Volume | 584,960 |
| Website | https://www.enliventherapeutics.com |
| Zip | 80,301 |